| |
| |
|
| Insider
Information: |
Goldberg Y. Paul |
| Relationship: |
VP of Clinical Develop... |
| City: |
Burnaby |
| State: |
A1 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
6,000 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
6,000 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Xenon Pharmaceuticals Inc. |
XENE |
VP of Clinical Develop... |
2015-09-24 |
6,000 |
2015-08-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
11 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| XENE |
Xenon Pharmaceuticals Inc... |
VP of Clinical Development |
• – – |
2015-09-24 |
4 |
S |
$8.60 |
$103,200 |
D/D |
(12,000) |
6,000 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
VP of Clinical Development |
• – – |
2015-09-24 |
4 |
S |
$8.60 |
$103,200 |
D/D |
(12,000) |
6,000 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
VP of Clinical Development |
• – – |
2015-09-23 |
4 |
S |
$9.02 |
$36,080 |
D/D |
(4,000) |
18,000 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
VP of Clinical Development |
• – – |
2015-09-23 |
4 |
S |
$9.02 |
$36,080 |
D/D |
(4,000) |
18,000 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
VP of Clinical Development |
• – – |
2015-09-22 |
4 |
S |
$9.33 |
$57,384 |
D/D |
(6,149) |
22,000 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
VP of Clinical Development |
• – – |
2015-09-22 |
4 |
S |
$9.33 |
$57,384 |
D/D |
(6,149) |
22,000 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
VP of Clinical Development |
• – – |
2015-09-22 |
4 |
D |
$9.53 |
$79,499 |
D/D |
(8,342) |
28,149 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
VP of Clinical Development |
• – – |
2015-09-22 |
4 |
D |
$9.53 |
$79,499 |
D/D |
(8,342) |
28,149 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
VP of Clinical Development |
• – – |
2015-09-22 |
4 |
OE |
$2.68 |
$98,513 |
D/D |
30,388 |
28,316 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
VP of Clinical Development |
• – – |
2015-08-18 |
4 |
D |
$11.00 |
$14,322 |
D/D |
(1,302) |
6,103 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
VP of Clinical Development |
• – – |
2015-08-18 |
4 |
OE |
$4.81 |
$15,189 |
D/D |
3,085 |
6,971 |
0 |
- |
|
11 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
